Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €10.08 EUR
Change Today -0.97 / -8.80%
Volume 0.0
SC7 On Other Exchanges
As of 2:11 PM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).

spectranetics corp (SC7) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/18/15 - €34.09
52 Week Low
09/30/15 - €9.98
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SPECTRANETICS CORP (SC7)

Related News

No related news articles were found.

spectranetics corp (SC7) Related Businessweek News

No Related Businessweek News Found

spectranetics corp (SC7) Details

The Spectranetics Corporation, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The company's vascular intervention product line includes crossing solutions, which support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions; peripheral atherectomy, a range of laser catheters for ablation of blockages in arteries above and below the knee; and coronary atherectomy and thrombectomy, which are aspiration for the treatment of blockages in the heart. Its primary crossing catheters include Quick-Cross, Quick-Cross Select, and Quick-Cross Extreme; the ELCA Laser Ablation Catheter for coronary atherectomy; and QuickCat aspiration catheter for thrombus management. The company's lead management product line comprises excimer laser sheaths, non-laser mechanical sheaths, and cardiac lead management accessories, such as Spectranetics Laser Sheath, and Lead Locking Device for the removal of pacemaker and defibrillator cardiac leads. It also offers the Stellarex DCB platform that is designed to treat peripheral arterial disease. The company sells its products in the United States, Canada, Europe, the Middle East, the Asia Pacific, Latin America, and Puerto Rico. The Spectranetics Corporation was founded in 1984 and is headquartered in Colorado Springs, Colorado.

753 Employees
Last Reported Date: 02/27/15
Founded in 1984

spectranetics corp (SC7) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $966.6K
Chief Operating Officer
Total Annual Compensation: $448.5K
Senior Vice President and General Counsel
Total Annual Compensation: $392.0K
Senior Vice President of Sales & Marketing fo...
Total Annual Compensation: $390.0K
Compensation as of Fiscal Year 2014.

spectranetics corp (SC7) Key Developments

Glancy Prongay & Murray LLP Files Securities Class Action Lawsuit Against The Spectranetics Corporation

Glancy Prongay & Murray LLP, representing investors of The Spectranetics Corporation has filed a class action lawsuit in the United States District Court for the District of Colorado on behalf of a class comprising purchasers of Spectranetics securities between February 19, 2015, and July 23, 2015, inclusive. The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose to investors that: the company was being negatively impacted by increasing competition; that the company’s sales force optimization efforts were inadequate; that, as a result, the company was performing below expectations; that the company lacked adequate internal controls; and that, as a result of the foregoing, Defendants’ statements about Spectranetics’s business, operations and prospects were false and misleading and/or lacked a reasonable basis.

Spectranetics Corp. Announces Executives Changes

On August 27, 2015, The Spectranetics Corporation announced that on August 23, 2015, Stacy McMahan accepted an appointment as Chief Financial Officer, effective on her date of hire, which is expected to be September 28, 2015. In this role, Ms. McMahan will report directly to Scott Drake, President and Chief Executive Officer. Ms. McMahan, age 51, has most recently served as Senior Vice President, Chief Financial Officer and Treasurer of MSA Safety Incorporated, since September 2013. Ms. McMahan will replace Guy Childs, who notified the Company of his decision to resign from his position as Chief Financial Officer on March 18, 2015. Mr. Childs will continue to serve as an employee of the Company.

The Spectranetics Corporation Completes Enrollment in ILLUMENATE Pivotal Study

The Spectranetics Corporation announced it has completed enrollment of 300 subjects in the ILLUMENATE Pivotal clinical study, a prospective, randomized controlled, multicenter study designed to assess the clinical performance of the Stellarex™ drug-coated angioplasty balloon used to restore and maintain blood flow to above-the-knee arteries of the leg in patients with peripheral arterial disease (PAD). The ILLUMENATE Pivotal study includes patients with superficial femoral or popliteal artery lesions, three to 14 cm in length, and will assess the safety and efficacy of Stellarex at 12 months, with follow-up to five years. Enrollment is now complete for all five studies in the ILLUMENATE series of clinical studies. Completion of clinical study enrollment is a major step toward premarket approval (PMA) with the U.S. Food and Drug Administration, which will be filed after one-year follow-up visits with all patients are completed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SC7:GR €10.08 EUR -0.97

SC7 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $13.12 USD 0.00
AtriCure Inc $18.26 USD 0.00
Cardiovascular Systems Inc $16.86 USD 0.00
CryoLife Inc $10.10 USD 0.00
Vascular Solutions Inc $32.33 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SC7 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SPECTRANETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at